NEW YORK (GenomeWeb) – Next-generation sequencing-based diagnostics firm Guardant Health today announced it raised $30 million in a Series B financing.

Khosla Ventures led the round and was joined by existing investor Sequoia Capital and new investor Pejman Mar Ventures.

The financing "will allow Guardant Health to accelerate the expansion of its commercial operations to support growing demand and ensure a distinctively high level of service for our physicians and patients," Guardant CEO and Co-Founder Helmy Eltoukhy said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.